3Benchimol El, Fortinsky KJ. Epidemiology of pediatric inflam- matory bowel disease:a systematic review of international trends [ J]. Inflamm Bowel Dis ,2011,17 ( 1 ) :423-39.
4Hyams J, Crandall W, Kugathasan S, et al. Induction and main- tenance infliximab therapy for the treatment of moderate-to-se- vere Crohn' s disease in children [ J ]. Gastroenterology, 2007, 132(3 ) :863-873.
5Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience [J]. J Crohns Colitis, 2012,6 (2) :143-153.
6Paul S,Del Tedesco E,Marotte H,et al. Therapeutic drug moni- toring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study [ J ]. Inflamm Bowel Dis, 2013,19 (12) :2568-2576.
7af Bjorkesten CG,Nieminen U ,Sipponen T ,et al. Mucosal heal- ing at 3 months predicts long-term endoscopic remission in anti- TNF-treated luminal Crohn'sdisease [ J ]. Scand J Gastroenterol, 2013,48 (5) :543-551.
8Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn' s disease [ J ]. Gastroenterology, 2005,128 (4) : 862-869.
9Kim MJ,Lee JS, Lee JH, et al. Inflixirnab therapy in children with Crohn's disease., a one-year evaluation of efficacy compa- ring top-down and step-up strategies [ J ]. Acta Paediatr, 2011, 100(3) :451-455.
10Falaiye TO, Mitchell KR, Lu Z, et al. Outcome Following Inflix- imab Therapy for Pediatric Patients Hospitalized With Refracto- ry Colitis-Predominant Inflammatory Bowel Disease[ J]. J Ped- iatr Gastroenterol Nutr,2013 Sep 16. [ Epub ahead of print].
